148 related articles for article (PubMed ID: 11311054)
1. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
Nugiel DA; Etzkorn AM; Vidwans A; Benfield PA; Boisclair M; Burton CR; Cox S; Czerniak PM; Doleniak D; Seitz SP
J Med Chem; 2001 Apr; 44(9):1334-6. PubMed ID: 11311054
[No Abstract] [Full Text] [Related]
2. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2).
Yue EW; Higley CA; DiMeo SV; Carini DJ; Nugiel DA; Benware C; Benfield PA; Burton CR; Cox S; Grafstrom RH; Sharp DM; Sisk LM; Boylan JF; Muckelbauer JK; Smallwood AM; Chen H; Chang CH; Seitz SP; Trainor GL
J Med Chem; 2002 Nov; 45(24):5233-48. PubMed ID: 12431051
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern.
Nugiel DA; Vidwans A; Etzkorn AM; Rossi KA; Benfield PA; Burton CR; Cox S; Doleniak D; Seitz SP
J Med Chem; 2002 Nov; 45(24):5224-32. PubMed ID: 12431050
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Moravcová D; Krystof V; Havlícek L; Moravec J; Lenobel R; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2989-92. PubMed ID: 12941318
[TBL] [Abstract][Full Text] [Related]
6. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
7. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
[TBL] [Abstract][Full Text] [Related]
8. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
[TBL] [Abstract][Full Text] [Related]
9. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.
Yue EW; DiMeo SV; Higley CA; Markwalder JA; Burton CR; Benfield PA; Grafstrom RH; Cox S; Muckelbauer JK; Smallwood AM; Chen H; Chang CH; Trainor GL; Seitz SP
Bioorg Med Chem Lett; 2004 Jan; 14(2):343-6. PubMed ID: 14698155
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
[TBL] [Abstract][Full Text] [Related]
13. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
Pevarello P; Brasca MG; Amici R; Orsini P; Traquandi G; Corti L; Piutti C; Sansonna P; Villa M; Pierce BS; Pulici M; Giordano P; Martina K; Fritzen EL; Nugent RA; Casale E; Cameron A; Ciomei M; Roletto F; Isacchi A; Fogliatto G; Pesenti E; Pastori W; Marsiglio A; Leach KL; Clare PM; Fiorentini F; Varasi M; Vulpetti A; Warpehoski MA
J Med Chem; 2004 Jun; 47(13):3367-80. PubMed ID: 15189033
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
16. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
[TBL] [Abstract][Full Text] [Related]
17. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
Cao Z; Yang F; Wang J; Gu Z; Lin S; Wang P; An J; Liu T; Li Y; Li Y; Lin H; Zhao Y; He B
J Med Chem; 2021 Oct; 64(20):15280-15296. PubMed ID: 34624191
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies of flavopiridol analogues.
Murthi KK; Dubay M; McClure C; Brizuela L; Boisclair MD; Worland PJ; Mansuri MM; Pal K
Bioorg Med Chem Lett; 2000 May; 10(10):1037-41. PubMed ID: 10843211
[TBL] [Abstract][Full Text] [Related]
19. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
20. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
